Josh Rothman practices patent and trade secret law in the pharmaceutical, biotechnology and medical device arenas. In addition to litigating complex cases in court for both the patentee and accused infringer, he counsels clients on due diligence matters in connection with mergers and acquisitions, as well as licensing and other transactional matters. He has significant experience litigating Hatch-Waxman cases, from pre-suit through appeal, involving blockbuster drugs such as Prilosec®, Accupril®, Imitrex®, Benicar® and Sensipar® including patents covering chemical compounds, polymorphs, enantiomers, salt and solvate forms, solid and sterile formulations, as well as methods of use and treatment.
In addition, Josh is also active in the firm’s pro bono practice. He has helped clients in obtaining Section VIII housing, U-visas, as well as disability benefits.
Amgen et al. v. Teva Pharmaceuticals, et al.
D. Del. (2011)
Josh Rothman successfully defended drug Sensipar® on behalf of clients Amgen and Brigham and Women’s Hospital challenged by two generic drug manufacturers in a Hatch-Waxman lawsuit. Amgen’s important calcimimetic drug Sensipar®, had worldwide sales of $651 million in 2009.